ArticleFrontiers in medicine2025
Identification and validation of novel risk genes for intervertebral disc disorder by integrating large-scale multi-omics analyses and experimental studies.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although genome-wide association studies (GWAS) have identified multiple genetic loci linked to intervertebral disc disorder (IDD), their functional characterization remains largely unelucidated. We aim to leverage an integrative analytical pipeline to identify novel IDD risk genes from genetic associations and experimentally validate their functional roles. Methods: We integrated transcriptome-wide association studies (TWAS), proteome-wide association studies (PWAS), expression and protein quantitative trait loci (eQTL and pQTL) colocalization analyses to identify potential causal genes for IDD. Enrichment analysis, expression profiling, protein-protein interaction (PPI) network construction, and druggability evaluation were also performed for the prioritized causal candidates. Subsequently, human intervertebral disc (IVD) tissues spanning degeneration grades and an Results: Integrative analysis of TWAS and PWAS with colocalization studies identified 104 genes and 10 proteins exhibiting causal associations with IDD. The identified genes/proteins were enriched in extracellular matrix organization, cellular senescence and collagen formation. Crucially, TMEM190, CILP2, and FOXO3 were demonstrated consistent evidence across TWAS, two independent PWAS datasets, and corresponding colocalization analyses, with CILP2 emerging as a potentially druggable target. Differential expression analysis revealed significant upregulated TMEM190 and CILP2, along with downregulated FOXO3 during IVD degeneration. These results were subsequently confirmed at protein levels in clinical specimens. Mouse model experiments further established that down-regulation of CILP2 alleviated IDD progression. Discussion: Collectively, this work provides an updated compendium of putative IDD risk genes and delineates pathogenic roles for TMEM190, CILP2, and FOXO3, providing a broad hint for further research on novel mechanism and therapeutic targets for IDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.